Cereno Scientific



Our vision is to develop innovative treatments to prolong life and improve quality of life for people with rare and common cardiovascular disease.

January – March

Q1 report 2024

Contents

Financial calendar

Interim Report, Q2 2024..... 29 August 2024
Interim Report, Q3 2024 ..... 21 November 2024
End-Of-Year Report, Q4 2024 ..... 25 February 2025
Interim Report, Q1 2025.....22 May 2025



Cereno Scientific in brief

June 2023

Listed on Nasdaq First North Growth Market

(CRNO B)

(Spotlight Aktietorget 2016–2023)

Cereno Scientific is a biotech developing innovative, effective, and safe treatments for patients affected by rare and common cardiovascular disease where great unmet medical needs persist.

Cardiovascular disease is the number one cause of death globally, killing nearly twice as many people as cancer. The term cardiovascular disease includes all diseases which involve the heart and/or the blood vessels. A majority of the complications associated with cardiovascular disease are caused by a blocking blood clot in a vein or artery. Many people affected by a blood clot can have as a consequence, for example, a heart attack, secondary heart failure, cardiac arrhythmias, stroke or other direct manifestations of blood clots in lungs or peripheral vessels.

Cereno's pipeline comprises:

- **Drug candidate CS1 in Phase II** is being developed as a treatment of the rare disease Pulmonary Arterial Hypertension (PAH).
- **Drug candidate CS014 soon to enter clinical phase** is being developed as a treatment for thrombosis prevention and a first-in-human Phase I study is expected to start in Q2 2024.
- **Drug candidate CS585 in preclinical phase** is being evaluated as a treatment for cardiovascular disease.

First quarter summary

Financial overview

	Group		Parent company	
(SEK)	Jan–Mar 2024	Jan–Mar 2023	Jan–Mar 2024	Jan–Mar-2023
Result after financial items	-15 437 724	-4 409 588	-15 233 285	-4 469 970
Earnings per share before dilution	-0.07	-0.03	-0.07	-0.03
Earnings per share after dilution*	-0.05	-0.03	-0.05	-0.03
Equity/assets ratio	74.5%	94.3%	74.5%	95.8%
Cash and bank balances	49 178 602	44 622 145	49 110 483	41 281 024

Earnings per share: Profit/loss for the period divided by 233,775,234 shares as of 31 March, 2024 and 137,514,844 shares as of 31 March, 2023.

* Earnings per share after dilution: Earnings for the period divided by the number of outstanding shares and the number of shares that can be subscribed for with outstanding options as of the balance sheet date 12/31/2023 and 12/31/2022, respectively.

Significant events during the first quarter

- On January 3, Cereno submitted a request to the FDA for Expanded Access, also called "Compassionate Use", to use CS1 in an extension of the ongoing Phase II trial evaluating CS1 in the rare disease Pulmonary Arterial Hypertension (PAH). The Expanded Access Program (EAP) will initially be limited to patients who have completed the Phase II study in PAH.

- On January 5, the Company announced that a research article on the innovative study design of the ongoing Phase II study of drug candidate CS1 in PAH had been published in the renowned medical journal Pulmonary Circulation. The research article concludes that CS1 represents a potential novel disease-modifying treatment for PAH.[1]

- On January 11, Cereno signed an agreement with CordenPharma, a Contract Development and Manufacturing Organization (CDMO). CordenPharma is contracted to perform a feasibility study and then manufacture drug candidate CS1.

- On January 12, the Company announced that Tatiane Abreu Dall'Agnol had joined the Company as Medical Director. She will be part of the Company's R&D team and report to Dr. Björn Dahlöf.

- On January 17, Cereno announced that drug candidate CS014, a novel histone deacetylase inhibitor (HDACi), had obtained an issued patent in the UK. This is the drug candidate's first patent, which strengthens the positioning of CS014.

- On January 22, Cereno announced that equity research company Edison Investment Research had been engaged by Cereno to produce regular, in-depth research for the Company. The intention is to raise the visibility of the Company and enable investors and stakeholders to develop an improved understanding of the business.

- On January 30, Cereno was granted approval by the FDA for Expanded Access, to investigational drug CS1 for use in an extension of the ongoing Phase II trial evaluating CS1 in PAH.

- On January 31–February 3, CEO Sten R. Sörensen, Dr. Raymond Benza, Network Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno's Scientific Advisory Board as well as CMO Dr. Björn Dahlöf, attended the PVRI 2024 Annual Congress organized by the Pulmonary Vascular Research Institute. The PVRI 2024 Annual Congress: "The next 50 years of pulmonary hypertension - a global view" is a top pulmonary vascular congress globally.

- On February 1, Megha Ranjan joined the Company as Project Director. She will be part of the Company's business and operational team and report to Sten R. Sörensen, Chief Executive Officer (CEO).

- On February 2, Julia Fransson joined the Company as Director of Business Development. Julia will develop value leverage to our BD strategies as well as work across functions to coordinate our commercial business focus.

[1] Benza RL, Adamson PB, Bhatt DL, Frick F, Olsson G, Bergh N, Dahlöf B. CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial. Pulm Circ. 2024; 14:e12323. https://doi.org/10.1002/pul2.12323

- On February 13, the Company announced that Dr. Rahul Agrawal, with a background in leading and/or co-designing close to 30 clinical trials with over 200,000 patients, had been appointed as Chief Medical Officer and Head of R&D.
- On February 13, Cereno announced an expansion of the Executive Management Team, with CEO Sten R. Sörensen, CSO Dr. Björn Dahlöf, Head of Preclinical Development Nicholas Oakes and Chief Financial Officer Eva Jagenheim, to include the newly appointed Chief Medical Officer & Head of Research & Development Dr. Rahul Agrawal and the Business Development Director Julia Fransson, to strengthen focus on the strategic priorities in the development programs.
- On February 21, Cereno updated on the Phase II study progress of CS1 in PAH. Investigators noted that most patients would like continued access to CS1 after the study. They expressed substantial interest in the FDA-approved EAP for patients who completed the study. The Company reported significant progress in the study, however, a slower recruitment pace than estimated during the last months and a longer start-up phase for two new clinics have affected the study timeline and topline results are expected in Q3 2024.
- On February 22, equity research company Edison Investment Research published its first, in-depth research on Cereno Scientific, with a valuation of 2.32 BSEK and a price of 9.90 SEK per share.
- February 29, Cereno shared further developments in the Phase II study of drug candidate CS1 in PAH.
- On March 4, Cereno announced that the exercise price for the warrants of series TO3 had been determined to 1.60 SEK per share of series B.
- On March 6, Cereno shared details on the study design for the EAP for its lead candidate drug, the HDACi CS1, in the rare disease PAH.
- On March 14, the Company sent out a notice to attend the Annual General Meeting, and an updated timeline bringing forward the AGM to April 16, and the Annual Report to March 26, 2024.
- On March 14, the Nomination Committee proposed Dr. Gunnar Olsson and CEO Sten R. Sörensen as new members of the Board of Directors.
- On March 14, Cereno announced that Don de Bethizy had been engaged as Senior Advisor to the Executive Management and Board of Directors of the Company.
- On March 18-20 CEO Sten R. Sörensen attended the partnering event BIO-Europe Spring.
- On March 19, the Company announced a new patent issued in Mexico for CS1.
- On March 21, Cereno announced that the TO3 warrants had been subscribed at 99.6 %, bringing in an additional 73.6 MSEK to the Company.
- On March 22, the Company announced that the drug candidate CS1's third patent family had been issued in 25 European countries following a completed validation and registration process.
- On March 26, Cereno published the Annual Report for 2023.

Significant events after the period

- On April 6–8, Sten R. Sörensen, CEO, Dr. Rahul Agrawal, CMO and Head of R&D, Dr. Björn Dahlöf, CSO and Fredrik Frick, Head of Clinical Operations, attended ACC's 73rd Annual Scientific Session & Expo (ACC.24) organized by the American College of Cardiology.
- On April 9, Cereno announced that a patent had been approved (Notice of Allowance) in Europe, in the first patent family for the preclinical Prostacyclin Receptor Agonist program, which includes drug candidate CS585.
- On April 10, the Company announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a First-In-Human, Phase I study of novel histone deacetylase inhibitor (HDACi) drug candidate CS014.
- On April 10–13, Dr. Rahul Agrawal, CMO and Head of R&D, and Dr. Björn Dahlöf, CSO, attended ISHLT 44th Annual meeting and Scientific sessions, organized by The International Society for Heart and Lung Transplantation, in Prague to meet global experts in the field of Pulmonary Hypertension.
- On April 11, Cereno announced that the Canadian authorities issued a patent for the drug candidate CS1's second patent family on Tuesday April 9.
- On April 16, the Annual General Meeting for the Company was held in Gothenburg.
- On May 2, Cereno announced the new Nomination Committee ahead of the Annual General Meeting 2025.

Letter from the CEO

The first quarter of 2024 has seen Cereno accomplish several important milestones on our mission to develop innovative, effective, and safe treatments to meet high unmet needs for patients suffering from rare and common cardiovascular diseases. CS1 was granted Expanded Access ("Compassionate Use") by the FDA, enabling patients with the rare and lethal disease Pulmonary Arterial Hypertension (PAH), who have completed our Phase II study, continued access to this potentially disease modifying drug. A successful TO3 financing brought 73.6 MSEK to the Company, further strengthening our ability to deliver on our development and commercial plans for our portfolio. Since the beginning of the year, several patents have been issued for the three drug candidates CS1, CS014 and CS585, bolstering their commercial potential. A few days after end of Q1, a Clinical Trial Application (CTA) for a first-in-human Phase I study of CS014 was sent to EMA, notably the most important milestone of the CS014 program so far. During the first months of the year, we have also substantially strengthened the Cereno team with several strategic recruitments with extensive experience in pharmaceutical development to help propel our pipeline and leverage our company's commercial position further.

We have our focus set on our most important milestones so far, the launch of a first-in-human Phase I study for CS014 and advancing the Phase II study of CS1 in PAH towards completion and reporting the results.

- Sten R. Sörensen, CEO

CS1 in Phase II study in PAH nearing conclusion

The CS1 program, our histone deacetylase inhibitor (HDACi) with epigenetic effects being developed in the rare and lethal disease PAH, kicked off 2024 with the approval of an Expanded Access Program (EAP) by the FDA on 30 January. The EAP will provide Cereno with the opportunity to, under a formal FDA-approved protocol, collect safety and efficacy data from long-term exposure to CS1 in patients with PAH. This initiative not only supports the treatment of PAH patients but also enables Cereno to gather additional CS1 documentation for regulatory discussions and Phase IIb/III pivotal study design planning. We continue to see a high level of interest in the EAP from patients and investigators and are working with the study sites to complete central and local approvals needed to start dosing patients. We are working towards finalizing the Phase II study of CS1 in PAH and we expect to share results in Q3 of 2024.

We are also happy to have extended the patent protection for CS1 with new patents approved in Mexico, Europe and Canada. These are all important pharmaceutical markets, and these patents play a significant role in building and strengthening the commercial potential of CS1.

The latest developments on CS1 comes on the heels of positive findings reported over the last months, suggesting potential clinical benefit of CS1 in patients. A previously reported Patient Case Study showed 30% reduction in pulmonary arterial pressure and 20% increase in cardiac output after 12 weeks of treatment, with an overall functional status improvement from NYHA/WHO functional class II to I at the end of the treatment period. Furthermore, a Data Quality Control Review (DQCR) during last autumn, of data obtained by the CardioMEMS HF System from the first 16 patients, showed a clinically meaningful reduction of pulmonary arterial pressure in several patients of a similar, or greater, magnitude as in the patient case.

CS014 soon to be a clinical candidate, first-in-human Phase I study pending approval

CS014, an HDAC inhibitor with epigenetic effects, represents a novel approach to effectively prevent arterial and venous thrombosis without the associated increased risk of bleeding in humans.

In the first quarter of 2024 the first patent for CS014 was granted. The patent was issued in the UK. This is a significant milestone for our CS014 project, as it builds the foundation for strong intellectual property rights around CS014, which will favorably support the drug candidate's position in the eyes of partners and investors.

Preparations for initiating a clinical first-in-human Phase I study, to primarily evaluate the safety and tolerability of CS014 in healthy volunteers, are on track, building on the successful completion of the preclinical safety program for CS014 in December 2023. A Clinical Trial Application (CTA) was sent to EMA on April 10, 2024. Once approved, the CTA will enable us to commence the first human trial with CS014, representing a significant advancement in our endeavor to prevent thrombosis in patients without causing bleeding in the future. The Phase I study will be conducted in Sweden in partnership with the contract research organization (CRO) Clinical Trial Consultants (CTC) and is targeted to start in Q2.

CS585, a promising antithrombotic treatment strategy

Cereno continues to secure a strong patent protection for our preclinical programs to support a favorable commercial positioning in future treatments for cardiovascular diseases. Our preclinical drug candidate CS585 has during the first months of 2024 been awarded an approved patent (Notice of Allowance) in Europe, in the first patent family for the preclinical Prostacyclin Receptor Agonist program.

We are eager to build on the momentum created in the scientific community following the article and commentary in the top-tier journal Blood in late 2023, concluding that CS585 could be a significant milestone to improve anti-thrombotic treatment strategies whilst minimizing the risk of bleeding. In 2024 new data will be presented on CS585, starting with an oral presentation at the prestigious EHA conference in Madrid 15th of June. With a growing body of evidence, we are methodically laying a solid foundation for a future selection of a clinical indication for CS585.

New Cereno team working seamlessly to reach our strategic goals

Cereno has made great advances towards our vision to provide valuable, more effective, and safer drug therapies to patients in need with rare and common cardiovascular diseases, in a challenging investment and market climate. The Cereno team, with several key recruits in the past months, have synched up well and are now working seamlessly to reach our set future milestones and to further propel our pipeline and strategic positioning of the Company. Shortly after Q1, we were happy to announce a strategic change of the Board of Directors, Cereno's Scientific's Advisory Board Member Dr. Gunnar Olsson and I joined the Board. The Nomination Committee's rationale for the new board composition, later approved at the Annual General Meeting, was to ensure that the board, as a whole, has competencies, experience and operational capacity well aligned with the Company's current development phase and growth strategy. We simultaneously announced that Don deBethizy, PhD, with more than 30 years of experience in managing and financing life science-related technologies and having played a key role in building and advising several life sciences companies, joined Cereno as Senior Advisor to the Executive Management Team and Board of Directors.

Expanding awareness of Cereno at Medical and Investor Events

During Q1, CMO & Head of R&D Dr. Rahul Agrawal, CSO Dr. Björn Dahlöf, Dr. Raymond Benza and I represented the Company at several medical conferences, investor and industry partnering events, such as PVRI 2024 Annual Congress in London, Life Science Day in Gothenburg, and BIO-Europe Spring in Barcelona. Post Q1, I was also present at the Bio€quity Conference in San Sebastian in May, meeting numerous key members of the Life Science investment community. These events have given us valuable insights into the current CVD research landscape as well as the opportunity to have fruitful discussions with potential partners, investors, and study investigators.

Future outlook

The warrants of series TO3 were exercised at approximately 99.6% in late March, injecting a total of 73.6 MSEK into Cereno. This high utilization rate of the warrants demonstrates the continued strong confidence that shareholders have in Cereno, in our vision and ability to develop innovative treatments for rare and common cardiovascular diseases.

During Q1, we received an in-depth analysis by the equity research company Edison, that values Cereno Scientific at 2.32 BSEK with a price of 9.90 SEK per share, pre CS014 first-in-human initiation and pre-Phase II topline results of our leading program CS1 in PAH. This valuation highlights the potential that lies within Cereno's pioneering and innovative pipeline of cardiovascular drug candidates.

We are grateful for the strong support shown by our highly engaged shareholders. The entire Cereno team remain dedicated to enhancing value for our shareholders by advancing our pipeline programs towards the future milestones set for each of them.

Looking ahead into the second quarter and into the summer, we have our focus set on our most important milestones so far, the launch of a first-in-human Phase I study for CS014 and advancing the Phase II study of CS1 in PAH towards completion and reporting the results.

Thank you for your support and for enabling us to break new ground in supporting patients with rare and common cardiovascular diseases.

May 2024

Sten R. Sörensen
Chief Executive Officer
Cereno Scientific

Project portfolio

Cereno has a promising project portfolio of innovative drug candidates focused on developing effective and safe treatments for rare and common cardiovascular diseases with major unmet medical needs. The Company's portfolio includes a Phase II program, one Phase I program and one preclinical program.

Clinical phase
Tolerability, safety and efficacy study

CS1
The drug candidate CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator through pressure-reducing, "reverse-remodeling", anti-fibrotic, anti-inflammatory and anti-thrombotic properties. CS1 is undergoing a Phase II clinical trial for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH).

CS014
The drug candidate CS014 is an HDAC inhibitor with epigenetic effects that is being developed as a treatment to effectively prevent thrombosis without increased risk of bleeding. CS014 has a pending CTA application to start a first-in-human Phase I study during Q2 2024.

Preclinical phase
Studies in the laboratory to fulfill requirements to start clinical studies

CS585
The drug candidate CS585 is being evaluated as a treatment for cardiovascular disease and further preclinical studies are ongoing to confirm a clinical indication.

Drug candidates in the portfolio



Cereno Scientific, pioneering HDAC inhibition in CVD

HDAC inhibitors are epigenetic modulators (changing gene expression without actually changing the genetic code) that have been shown to have a wide spectrum of potentially disease-modifying effects in CVD.

Research has indicated that HDACi can mitigate elevated blood pressure, inflammation, fibrosis, and reverse vascular changes, all of which are hallmark features of widespread and severe cardiovascular diseases.

Clinical Phase II drug candidate CS1

The drug candidate CS1 is an HDAC inhibitor that works through epigenetic modulation, being developed as a treatment for the rare disease Pulmonary Arterial Hypertension (PAH). CS1 has the potential to be an effective, safe and disease-modifying drug. The aim of CS1's development is to offer improved quality of life and prolonged life for patients with PAH. A Phase II study in the USA is ongoing in collaboration with the global healthcare company Abbott.

CS1's unique efficacy profile addresses the underlying pathophysiology of PAH.
CS1 is an innovative formulation of valproic acid (VPA) that has received Orphan Drug Designation (ODD) for the treatment of PAH. CS1's active substance VPA works through epigenetic modulation with a multifold efficacy profile that is arterial pressure-reducing, reverse-remodeling and has anti-fibrotic, anti-inflammatory, and anti-thrombotic properties.

CS1's multi-fold disease modifying characteristics:



CS1's unique efficacy profile addresses many of the pathogenetic mechanisms of the rare disease PAH and is believed to be able to address today's major unmet need for better treatment alternatives, and to have potential as a novel disease-modifying treatment in the future.

The FDA grants national Orphan Drug Designation to encourage the development of drugs intended for the treatment of rare diseases in the US. Several incentives are associated with orphan drug status to facilitate drug development and they include, among other things, seven years of market exclusivity in the US from approval, assistance from the FDA in the design of further clinical studies, and tax credits for qualified study costs.

CS1's properties have been demonstrated through in-vitro models, animal models, human physiological data, independent epidemiological studies and a successfully completed Phase I study. In preclinical and clinical studies investigating anti-thrombotic effects, CS1 showed an improvement of the endogenous fibrinolytic system by supporting local thrombolysis of impending occlusive thrombosis through the effect on local release of t-PA and reduction of the blood levels of PA-1. In the Phase I clinical trial, CS1 demonstrated good safety and tolerability, robust reduction of PAI-1 and no problems with bleeding.

The development program for CS1 in PAH is further supported with the ODD granted by the US FDA in March 2020. Through the granted ODD, the FDA has also indicated that they believe that CS1 has the potential to offer patients with PAH a significantly improved treatment.

Phase II study in PAH

A Phase II clinical trial is ongoing to evaluate CS1's safety and tolerability as well as investigate exploratory efficacy in patients with PAH.

The primary objective of the study is to evaluate the safety and tolerability of the drug candidate CS1. Other standard endpoints used in the ongoing PAH study for this patient group will also be evaluated in an exploratory fashion. A validated estimate of risk is also calculated besides various biomarkers, quality of life and aspects of cardiac function.

The Phase II study is being conducted at ten different specialist clinics in the USA, with one additional clinic in late start-up phase. Topline results are expected in Q3 2024.

The collaboration with the global healthcare company Abbott allows Cereno to use Abbotts pioneering implantable technology CardioMEMS HF System in the ongoing Phase II-study with CS1 in PAH.

The technology is used to be able to monitor pulmonary arterial pressure and other cardiopulmonary function of patients in the study on a daily basis. Continuous monitoring enables the use of a smaller patient population, enhancing resource efficiency in conducting the study – a key element in Cereno's pursuit of innovative clinical development methods. In addition, the function of the heart can be measured to see an effect of the medication with CS1.

CardioMEMS is a safe method already approved for monitoring in heart failure. With the current Phase II study, Abbott also gets the opportunity to test its system on a new disease indication. The study has received recognition for its innovative study design.



The Phase II study with CS1 in PAH is run at 10 different clinics in the US, with one additional clinic in start-up phase

Primary endpoint	Secondary exploratory endpoints

Safety and tolerability as measured by:
• AEs
• Adverse events of special interest (AESIs)
• Serious adverse events (SAEs)
• Adverse device effects (ADEs) related to the CardioMEMS™ system incl. unexpected serious adverse device effects (USADEs)
• Laboratory parameter abnormalities
• Change in vital signs
• Bleedings
• Change in ECG parameters
	Change from baseline and difference between doses
	• **Pulmonary Vascular Resistance, cardiac /pulmonary hemodynamics from RHC**
	• **RRS 2,0**
	• **REVEAL lite 2**
	• **Pharmacokinetics**
	• Need for additional therapy
	• NYHA/WHO FC
	• Quality of life (SYMPACT)
	• Minnesota Living with HF Q
	• Hospitalizations; PAH related and other
	• CV morbidity and mortality; PAH related/other
	• **6MWD**
	• **Actigraphy** (device to measure motor activity)
	• eGFR
	• NT-pro-BNP, ST2, PAI-1
	• Other biomarkers TBD (Biobank)
	• **From CardioMEMS™**
	  • sPAP, dPAP, mPAP
	  • Other calculated RV variables and TPR
	• **Echocardiography**
	  • Morphology and Function Left Ventricle
	  • Morphology and Function Right Ventricle
	• **MRI in sync with CardioMEMS™**
	  • Morphology and Function Left Ventricle
	  • Morphology and Function Right Ventricle

RHC: Right heart catheterization, RRS: REVEAL Risk Score, FC: Functional class, 6MWD: Six-Minute Walk distance, PAP: Pulmonary Arterial Pressure, RV: Right Ventricle, TPR: Total Peripheral Resistance

What can we expect from the Topline results from CS1-003 study in PAH?

The ongoing Phase II trial of CS1 intends to primarily evaluate CS1's safety and tolerability and also explore efficacy in patients with PAH. We aim to assess whether the safe therapy with CS1 also demonstrates positive outcomes in efficacy parameters, hemodynamic measures, patient-reported outcomes (quality of life), and biomarkers. This data will provide crucial insights for planning the subsequent pivotal trial of CS1 in PAH.

- Dr. Rahul Agrawal, Chief Medical Officer (CMO) and Head of R&D

Current status of CS1

Cereno Scientific has during the last few months reported positive findings from the ongoing study suggesting a potential clinical benefit of drug candidate CS1 in patients with the severe rare disease PAH. Further details of the trial need to be awaited to support these findings.

Remarkable Patient Case Study data

A patient case study performed on the first patient having completed the study at a specific clinic showed remarkable efficacy data. In 12 weeks of treatment with CS1, the patient showed a 30% reduction in pulmonary arterial pressure and a 20% increase in cardiac output. The patient's overall functional status was changed from NYHA/WHO functional class II to I at the end of the treatment period, meaning that the patient had next to normal functional physical capacity with CS1 added to stable conventional therapy.

In addition to the data related to the effects of CS1 in the PAH patient, the case study indicates that using the CardioMEMS permits safe daily remote monitoring of pulmonary arterial (PA) pressure over time in patients with PAH, permitting assessment of medication effectiveness on an individual patient level.

Positive findings from the Data Quality Control Review

Cereno reported in October 2023 that a Data Quality Control Review (DQCR), of data obtained by the CardioMEMS HF System from the first 16 patients, was concluded with positive findings. The data quality of the CardioMEMS measurements was found satisfactory with adherence to study protocol and with timely data transfers from the patient's home to the clinic. Initial efficacy findings showed a clinically meaningful reduction of pulmonary arterial pressure in several patients, included in the data quality control, of a similar or greater magnitude as in the Patient Case.

The DQCR findings are not based on data from all patients participating in the Phase II study and some patients in this analysis have not completed the full study period. The final results of the study may differ from the findings in this DQCR and should not in any way be seen as a guarantee regarding the outcome and conclusions of the upcoming final Phase II study results.

Expanded Access Program for CS1 in PAH

Since January 30th 2024, CS1 is approved by the FDA for Expanded Access, an extension of the ongoing Phase II trial evaluating CS1 in PAH. The Expanded Access Program (EAP) will provide Cereno with the opportunity to, under a formal FDA-approved protocol, collect safety and efficacy data from long-term exposure to CS1 in patients with PAH. This initiative not only supports the treatment of PAH patients but also enables Cereno to gather additional CS1 usage documentation for regulatory discussions and Phase IIb/III pivotal study design planning.

FDA definition of Expanded Access

Sometimes called "Compassionate Use", Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

Novel HDACi CS014

The investigational drug candidate CS014 belongs to the HDAC inhibitor program consisting of HDAC inhibitors that act through epigenetic modulation. In March 2019, CS014 was acquired from Emeriti Bio and has since been developed in a collaboration between Cereno, Emeriti Bio and University of Michigan.

CS014 represents a novel approach to effectively prevent arterial and venous thrombosis, potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity (NCE) with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. Given the potential for the additional disease-modifying properties seen with HDAC inhibition, further cardiovascular benefits of CS014 may be expected, including amelioration of inflammation, fibrosis, vascular changes and elevated systemic and pulmonary blood pressure. HDAC inhibition as thrombosis prevention has the opportunity to fundamentally change the thrombosis prevention landscape and meet a major unmet medical need.

Preclinical data suggests that CS014 is an effective HDAC inhibitor that inhibits platelet activity, fibrin accumulation and small and large vessel thrombosis while maintaining hemostasis in a dose-dependent manner. Also, when combined with rivaroxaban, CS014 inhibited the formation of platelet and fibrin-rich thrombosis without adding to the bleeding risk.[2] These cumulated data show that CS014 has the potential to enrich the toolbox of antithrombotic therapies in both venous and arterial thrombosis. With clinical use of the HDAC inhibitor CS014, through epigenetic modulation, it could be possible to prevent thrombosis without an increased risk of bleeding, a much-desired unmet medical need. Additional preclinical and clinical studies will be conducted to determine the first indication where CS014 has the greatest potential as a treatment to prevent thrombosis.

Current status of CS014 development

Preparations for initiating a clinical first-in-human Phase I study are ongoing and on track. The preclinical safety program for CS014 was successfully completed in December 2023. The safety documentation is a key component needed to apply for permission from regulatory authorities to start a first-in-human Phase I study. Furthermore, a contract research organization has been engaged to conduct the trial, and the Clinical Trial Application (CTA) was submitted to the European Medicines Agency in April 2024.

Cereno aims to be able to start the first-in-human Phase I study with CS014 in the second quarter of 2024.

[2] Stanger L, Holinstat M, Lambert S, Yalavarthi P, Bergh N, Dahlof B. HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding. Poster presented at: 65th ASH Annual Meeting & Exposition; December 9, 2023; San Diego, USA. https://ash.confex.com/ash/2023/webprogram/Paper186602.html

Novel IP Receptor Agonist CS585

Drug candidate CS585 is a highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.

Preclinical data suggest that CS585 provides a new option of activating the IP receptor to decrease platelet reactivity and could represent the first viable option for targeting the IP-receptor on platelets for inhibition of thrombosis with a reduced risk of bleeding. The preclinical results with CS585, including a head-to-head comparison of CS585 and the FDA-approved IP receptor agonists selexipag and iloprost, indicate a favorable profile for inhibiting platelet activation and clot formation. CS585 was shown to be more selective and have a more sustained efficacy than the currently available IP receptor agonists.[3] CS585 also demonstrate a sustained duration of action in mice in the ability to inhibit platelet activation through several routes of administration including oral.

The growing body of evidence around drug candidate CS585 supports favorable tolerability and efficacy in preclinical studies. Recently, the early results from CS585 were published in the top-tier journal Blood[4] showing that CS585 is a highly potent and selective compound given both orally and intravenously and prevents thrombosis for up to 48 hours as observed in preclinical studies. Following the publication, a commentary article[5] and the Blood Podcast[6] highlighted that the new preclinical findings of CS585 could be a significant milestone to improve anti-thrombotic treatment strategies without bleeding.

A license agreement for drug candidate CS585 with the University of Michigan provides Cereno exclusive rights to further development and commercialization of CS585.

Research collaboration with the University of Michigan

The University of Michigan, located in Ann Arbor, Michigan, USA, is a leading public research institution renowned for its successful collaborations with the pharmaceutical industry. Dr. Michael Holinstat, an esteemed pharmacologist with a PhD from the University of Illinois in Chicago, heads Cereno's two preclinical programs at the University. He also serves as a Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan, leading translational programs in drug development for hemostasis and thrombosis. Dr. Holinstat's extensive research spans thrombosis, pharmacology, and hematology, and he has established a cutting-edge laboratory for studying pharmacological effects on platelets and coagulation, both in vitro and in vivo.

[3] Stanger L, Yalavarthi P, Lambert S, Rickenberg A, Goerger K, Gilmore D, Dahlof B, Bergh N, Holinstat M. CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists. Poster presented at: 65th ASH Annual Meeting & Exposition; December 9, 2023; San Diego, USA. https://ash.confex.com/ash/2023/webprogram/Paper186300.html

[4] Stanger L, Yamaguchi A, Yalavarthi P, Lambert S, Gilmore D, Rickenberg A, Luke C, Kumar K, Obi AT, White A, Bergh N, Dahlöf B, Holinstat M. The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor Blood (2023) 42(18):1556–1569. https://doi.org/10.1182/blood.2023020622.

[5] Rondina MT. Targeting prostacyclin: all gain with no pain? Blood (2023) 142(18):1506–1507. https://doi.org/10.1182/blood.2023022227.

[6] Blood Podcast. (2023, November 2) *Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging.* (Audio podcast). Retrieved from https://ashpublications.org/blood/pages/blood_podcast_s6_ep18.

The group's performance, January-March 2024

Financial performance

During quarter one, the company has mainly invested in the implementation of the Phase II clinical study with CS1 in PAH, in the development of the patent portfolio, and in preclinical studies with CS585 and CS014. At the end of the quarter, the group had a cash balance of SEK 49 million and an equity ratio of 74.5%.

Risk factors

A number of risk factors can have a negative impact on Cereno Scientific's operations. It is therefore of great importance to take into account relevant risks in addition to the company's growth opportunities. These risks are described without mutual arrangement and without claims to be comprehensive in the company's prospectus issued in connection with the latest rights issue in May 2023 and which can be read on the Company's website.

Company structure and shareholding

Cereno Scientific Group comprises parent company Cereno Scientific AB and its US subsidiary Cereno Scientific Inc. The US subsidiary was formed on 20 December 2019, and is wholly owned by Cereno Scientific AB.

Company share

Cereno Scientific's B shares were listed on Spotlight Stock Market on 22 June 2016. Since 1 July 2023, the share is traded on Nasdaq First North Growth Markets as "CRNO B" ISIN-code SE0008241558. Certified Adviser is Carnegie Investment Bank AB, Regeringsgatan 56, 103 38 Stockholm.

Share capital

Cereno Scientific's share capital was, as of the balance sheet date 31 March 2024, divided into 233,775,234 shares. The company has two classes of shares, of which 722,248 are A shares. The A share gives ten (10) votes per share. Each B share gives one (1) vote per share. Each share carries an equal right to a share in the company's assets and results. The share's quota value (share capital divided by the number of shares) amounts to SEK 0.10.

Warrants of convertible loans

The financing agreement concluded with the European High Growth Opportunities Securitization Fund on 1 March 2019 and consisted of convertible loans and associated warrants. The company no longer has any outstanding convertible loans. During December 2021 Cereno Scientific repurchased 1,105,262 warrants. There are no warrants that remain outstanding after March 2024.

Warrants of series 2019/2023 N01 and series 2019/2023 S01

The Extraordinary General Meeting on 28 August 2019 resolved to issue 650,000 warrants, of which 450,000 relate to key persons (series 2019/2023 N01) and 200,000 relate to operational Board members (series 2019/2023 S01). After the completed share issue in September 2022, the restated

number of Class B shares that the warrants give entitlement to is 907,071 with a subscription price of SEK 10.94. The warrants can be used for subscribing for Class B shares during the period 1 April – 31 October 2023.

Warrants of series 2019/2023 SAB01

On 6 September 2019, the Board of Directors of Cereno Scientific resolved to issue 300,000 warrants to members of the company's Scientific Advisory Board (series 2019/2023 SAB01). After the completed share issue in September 2022, the restated number of Class B shares that the warrants give entitlement to is 418,648 with a subscription price of SEK 10.94. The warrant can be used for subscribing for Class B shares during the period from 1 April 2023 to 31 October 2023.

Long-term employee stock option program (qualified employee stock options) for employees

The Extraordinary General Meeting on 28 February 2022 resolved to implement a long-term incentive program for employees of the company, through the issue of not more than 3,000,000 qualified employee stock options, which will be granted to the participants without consideration. Each stock options entitles the participant to acquire one new share of series B in the company at an exercise price amounting to SEK 0.10, equivalent of the share's quota value. Allocation of stock options to the participants shall be made no later than 31 December 2022. The allocated stock options vest for 36 months and may only be utilized to acquire new shares if the participant still is an employee of the company and all other requirements for qualified employee stock options under the Swedish Income Tax Act are fulfilled. The participant may utilize allocated and vested stock options from the end of the vesting period up to and during the entire tenth year calculated from the date of allocation. The Meeting also resolved to issue not more than 3,000,000 warrants to enable delivery of new shares to the participants of the program. After the completed share issue in May 2023, the restated number of Class B shares that the warrants give entitlement to is 1,754,719.

Long-term employee stock option program (qualified employee stock options) for board members

The Extraordinary General Meeting on 28 February 2022 resolved to implement a long-term incentive program for board members of the company, through the issue of not more than 1,111,111 qualified employee stock options, which will be granted to the participants without consideration. Each stock options entitles the participant to acquire one new share of series B in the company at an exercise price amounting to SEK 0.10, equivalent of the share's quota value. Allocation of stock options to the participants shall be made no later than 31 December 2022. The allocated stock options vest for 36 months and may only be utilized to acquire new shares if the participant still is a board member or otherwise remain engaged in the company and all other requirements for qualified employee stock options under the Swedish Income Tax Act are fulfilled. The participant may utilize allocated and vested stock options from the end of the vesting period up to and during the entire tenth year calculated from the date of allocation. The Meeting also resolved to issue not more than 1,111,111 warrants to enable delivery of new shares to the participants of the program. In total, 1,111,110 warrants were allocated to board members up until December 31, 2022. Taking into account board members who are no longer members of the Board, the total number of allocated warrants that remain are 444,444. After the completed share issue in May 2023, the restated number of Class B shares that the warrants give entitlement to is 467,925.

Implementation of a long-term incentive program (warrants)

The Extraordinary General Meeting on 28 February 2022 resolved to implement a long-term incentive program for certain key individuals in the company that cannot be allocated qualified employee stock options, through the issue of not more than 3,333,333 warrants. After the completed share issue in September 2022, the restated number of Class B shares that the warrants give entitlement to is 3,613,910. Of these, 831,199 had been allocated as of 31 March 2023. The warrants shall be issued the company and then be transferred to participants in the program at a price corresponding to the warrants' market price at the time of the transfer, calculated pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the company at a subscription price corresponding to 150 percent of the volume-weighted average share price during the fifteen-day period which immediately precedes allocation. Subscription for new shares by virtue of the warrants shall be made during a one-year period starting three years from allocation. It was further resolved that board members and deputies shall be entitled to participate in the program.

Warrants of series 2023/2026:1 and series 2023/2026:2

The Extraordinary General Meeting on September 14 2023 resolved to issue 13,000,000 warrants of series 2023/2026:1 to be transferred to employees at market price, calculated pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the company at a subscription price of 2 SEK. The subscription time is set to Nov 16 to Nov 30, 2026. The extraordinary General Meeting resolved to issue 7,000,000 warrants to some Members of the Board. The warrants of series 2023/2026:2 are transferred to the board members at market price, calculated pursuant to the Black-Scholes model. Each warrant entitles to subscription for one new share of series B in the company at a subscription price of 2 SEK. The subscription time is set to Nov 16 to Nov 30, 2026.

Warrants of series 2023/2026:3 and series 2023/2026:4

The Extraordinary General Meeting on November 7 2023 resolved to issue 250,000 warrants of series 2023/2026:4 to be transferred to employees at market price, calculated pursuant to the Black-Scholes model. One (1) Warrant of series 2023/2026:3 provides the right during the period from 30 November 2026 up to and including 14 December 2026 subscribe to one Share at a Subscription Price amounting to 200 percent of the volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the period from and including 24 October 2023 until and including 6 November 2023, however, never lower than the Shares' quota value. The extraordinary General Meeting resolved to issue 1,000,000 warrants to a new Member of the Board. The warrants of series 2023/2026:4 are transferred to the board member at market price, calculated pursuant to the Black-Scholes model. One (1) Warrant of series 2023/2026:3 provides the right during the period from 30 November 2026 up to and including 14 December 2026 subscribe to one Share at a Subscription Price amounting to 200 percent of the volume-weighted average price of the Company's share of series B on Nasdaq First North Growth Market during the period from and including 24 October 2023 until and including 6 November 2023, however, never lower than the Shares' quota value.

The Extraordinary General Meeting on December 12 2023 resolved, in accordance with the board of director's proposal, to adjust the terms and conditions for the warrants of series 2023/2026:1 and 2023/2026:4, respectively, and necessary adjustments of the agreements between the holders of the warrants and the Company related to the respective incentive program.

The general meeting also resolved, in accordance with a shareholder groups' proposal, to adjust the terms and conditions for the warrants of series 2023/2026:1 and 2023/2026:4, respectively, and necessary adjustments of the agreements between the holders of the warrants and the Company related to the respective incentive program.

Audit

The company's auditor has not audited the Interim Report.

Principles of preparation for the Interim Report

The accounts in this Interim Report have been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board BFNAR 2012:1 Annual Report and Consolidated Accounts (K3).

Financial calendar

Interim Report, Q2 2024.....29 August 2024
Interim Report, Q3 2024 .....21 November 2024
End-Of-Year Report, Q4 2024 .....25 February 2025
Interim Report, Q1 2025.....22 May 2025

Share capital development

Year	Event	Ratio value (SEK)	Difference shares	Change (SEK)	Total number shares	Total share capital (SEK)
2012	Rights issue	1	50 000	50 000	50 000	50 000
2012	Directed issue	1	10 605	10 605	60 605	60 605
2016	Stock dividend issue	1	1 200	1 200	61 805	61 805
2016	Share split 100:1	10		556 245	61 805	618 050
2016	Subdivision A-/B- shares	0.10	6 118 695		6 180 500	618 050
2016	Directed issue	0.10			6 180 500	
2016	Directed issue	0.10	1 420 000	1 420 000	7 600 500	760 050
2016	IPO	0.10	450 000	45 000	8 050 500	805 050
2016	Conversion	0.10	2 940 000	294 000	10 990 500	1 099 050
2018	Conversion	0.10	188 679	18 868	11 179 179	1 117 918
2018	Conversion	0.10	444 444	44 444	11 623 623	1 162 362
2018	Conversion	0.10	540 540	54 054	12 164 163	1 216 416
2018	Conversion	0.10	483 870	4 838 700	12 648 033	1 264 803
2018	Conversion	0.10	419 354	41 935	13 067 387	1 306 739
2018	Conversion	0.10	384 614	38 461	13 452 001	1 345 200
2018	Conversion	0.10	269 230	26 923	13 721 231	1 372 123
2018	Conversion	0.10	307 692	30 769	14 028 923	1 402 892
2018	Conversion	0.10	333 333	33 333	14 362 256	1 436 226
2018	Conversion	0.10	285 714	28 571	14 647 970	1 464 797
2019	Conversion	0.10	533 333	53 333	15 181 303	1 518 130
2019	Conversion	0.10	666 666	66 667	15 847 969	1 584 797
2019	Conversion	0.10	3 333 333	333 333	19 181 302	1 918 130
2019	Rights issue	0.10	19 181 302	1 918 130	38 362 604	3 836 260
2019	Overallotment issue	0.10	1 724 137	172 414	40 086 741	4 008 674
2019	Remuneration issue	0.10	132 571	13 257	40 219 312	4 021 931
2020	Directed issue	0.10	31 600 000	3 160 000	71 819 312	7 181 931
2021	Share issue TO1	0.10	33 442 470	3 344 247	105 261 782	10 526 178
2022	Share issue TO2	0.10	32 253 062	3 225 306	137 514 844	13 751 484
2023	Rights issue	0.10	96 260 390	9 626 039	233 775 234	23 377 523
At end of period		**0.10**	**96 260 390**		**233 775 234**	

Number of average shares

	Jan–Mar 2024	Jan–Mar 2023	Jan–Dec 2023
Before diluted	185 645 039	137 514 844	185 645 039
After diluted	228 455 687	146 255 418	228 455 687

Share and owners

The largest shareholders by 31 March 2024.

Owners	Capital	Votes
Avanza Pension	21.1 %	20.6 %
Pareto Securities AS	3.2 %	3.0 %
Jern Claes Sverker	0.7 %	1.6 %
Butt Jan	1.4 %	1.4 %
Bergh, Olof Niklas	0.5 %	1.4 %
Ejlegard, Andreas	1.2 %	1.1 %
Nordnet Pensionsförsäkring	1.2 %	1.1 %
Lundberg, Mårten	1.0 %	1.0 %
Borgquist, Niklas	0.9 %	0.9 %
Total ten largest owners	**32.9 %**	**33.7 %**
Other shareholders	67.1 %	66.3 %
Total (7 381 shareholders)	**100 %**	**100 %**

Group – Income statement

(SEK)	1 Jan 2024 31 Mar 2024 3 months	1 Jan 2023 31 Mar 2023 3 months	1 Jan 2023 31 Dec 2023 12 months
Net sales	.	.	.
Capitalised work for own account	21 612 407	15 426 614	49 276 646
	21 612 407	**15 426 614**	**49 276 646**
Operating expenses			
Other external costs	-28 668 575	-16 591 438	-71 152 162
Personnel costs	-6 270 410	-3 092 281	-18 748 415
Depreciation of tangible fixed assets	-3 577	-3 577	-14 308
Other operating items	-511 134	-149 636	-4 011 820
Operating loss	**-13 841 289**	**-4 410 318**	**-44 650 060**
Loss from financial items			
Interest income and similar income	1 980	735	1 840 942
Interest expenses and similar expenses	-1 598 415	-5	-5 297 093
Loss after financial items	**-15 437 724**	**-4 409 588**	**-48 106 210**
Loss before tax	**-15 437 724**	**-4 409 588**	**-48 106 210**
Income taxes	-	-	-
Loss for the period	**-15 437 724**	**-4 409 588**	**-48 106 210**

Group – Balance sheet

(SEK)	31 Mar 2024	31 Mar 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalised expenditures for development activities	204 095 702	150 960 551	182 483 295
Patents, trademarks, licenses and similar rights	13 780 255	11 452 967	13 780 255
	217 875 957	**162 413 518**	**196 263 550**
Tangible assets			
Fixtures, tools and installations	10 738	25 046	14 315
	10 738	**25 046**	**14 315**
Financial assets			
Other long-term receivables	9 761	9 526	9 264
	9 761	**9 526**	**9 602**
Total fixed assets	**217 896 456**	**162 448 090**	**196 287 129**
Current assets			
Current receivables			
Other receivables	1 331 261	867 764	1 123 911
Prepaid expenses and accrued income	1 324 355	956 758	406 641
	2 655 616	**1 824 522**	**1 530 552**
Cash and bank balance	**49 178 602**	**44 622 145**	**87 168 535**
Total current assets	**51 834 218**	**46 446 667**	**88 699 087**
TOTAL ASSETS	**269 730 674**	**208 894 757**	**284 986 216**

Group – Balance sheet cont.

(SEK)	31 Mar 2024	31 Mar 2023	31 Dec 2023
EQUITY AND LIABILITIES			
Equity			
Share capital	23 377 523	13 751 484	23 377 523
Other contributed capital	297 413 530	245 725 032	297 413 530
Other capital including loss for the year	-119 797 188	-62 431 528	-104 366 617
Equity attributed to the Parent Company's shareholders	**216 424 436**	**201 511 420**	**216 424 436**
Total equity	**200 993 865**	**197 044 988**	**216 424 436**
Long-term liabilities			
Other liabilities to credit institutions	45 400 000	400 000	45 400 000
	45 400 000	**400 000**	**45 400 000**
Current liabilities			
Accounts payable	18 611 654	7 156 820	6 930 366
Tax liabilities	-	267 632	-
Other liabilities	1 744 006	443 819	1 231 118
Accrued expenses and deferred income	2 981 149	3 581 498	15 000 296
	23 336 809	**11 449 769**	**23 161 780**
TOTAL EQUITY AND LIABILITIES	**269 730 674**	**208 894 757**	**284 986 216**

Group – Change in equity

01 January – 31 March 2023	Share capital	Other contributed capital	Other capital including profit/ loss for the year
At start of period	13 751 484	245 725 032	-57 965 096
Exchange rate differences when translating foreign subsidiaries	-	-	-56 844
Loss for the period	--	-	-4 409 588
At the end of the period	**13 751 484**	**245 725 032**	**-62 431 528**

01 January – 31 March 2024	Share capital	Other contributed capital	Other capital including profit/ loss for the year
At start of period	23 377 523	297 413 530	-104 366 617
Exchange rate differences when translating foreign subsidiaries	-	-	7 153
Loss for the period	-	-	-15 437 724
At the end of the period	**23 377 523**	**297 413 530**	**-119 797 188**

01 January – 31 December 2023	Share capital	Other contributed capital	Other capital including profit/ loss for the year
At start of period	13 751 484	245 725 032	-57 965 096
Qualified Personnel Warrants	-	-	1 670 687-
Exchange rate differences when translating foreign subsidiaries	-	-	34 002
New share issue	9 626 039-	67 382 273-	-
Issue expenses	-	-15 693 775-	-
Loss for the period	--	-	-48 106 210
At the end of the period	**23 377 523**	**297 413 530**	**-104 366 617**

Group – Cash flow statement

(SEK)	1 Jan 2024 31 Mar 2024 3 months	1 Jan 2023 31 Mar 2023 3 months	1 Jan 2023 31 Dec 2023 12 months
OPERATING ACTIVITIES			
Loss after financial items	-15 437 724	-4 409 588	-48 106 210
Depreciations	3 577	3 577	14 308
Translation differences	7 153	-56 844	34 002
Accrued interest cost	-	-	777 040
Qualified Personnel warrants	-	-	1 670 687
	-15 426 994	**-4 462 855**	**-45 610 173**
Cash flow from operating activities before changes in working capital	**15 426 994**	**-4 462 855**	**-45 610 173**
Cash flow from changes in working capital			
Increase (-)/Decrease (+) in operating receivables	1 125 562	-241 606	52 288
Increase (+)/Decrease (-) in operating liabilities	175 029	-2 292 458	8 642 852
Cash flow from operating activities	**-16 377 527**	**-6 996 919**	**-36 915 033**
Investing activities			
Acquisition of intangible assets	-21 612 407	-15 426 615	-49 276 646
Cash flow from investing activities	**-21 612 407**	**-15 426 615**	**-49 276 646**
Financing activities			
New share issue	-	-	77 008 311
Issue expenses	-	-	-15 693 775
Resolve of warrant subscription right			45 000 000
Cash flow from financing activities	**0**	**0**	**106 314 536**
Cash flow for the period	**-37 989 934**	**-22 423 534**	**20 122 856**
Cash and cash equivalents at start of period	**87 168 535**	**67 045 679**	**67 045 679**
Cash and cash equivalents at end of period	**49 178 602**	**-22 423 534**	**87 168 535**

Parent company – Income statement

(SEK)	1 Jan 2024 31 Mar 2024 3 months	1 Jan 2023 31 Mar 2023 3 months	1 Jan 2023 31 Dec 2023 12 months
Net sales	-	-	-
Capitalised work for own account	21 612 407	15 426 614	49 276 646
	21 612 407	**15 426 614**	**49 276 646**
Operating expenses			
Other external costs	-28 464 137	-16 651 820	-71 227 587
Personnel costs	-6 270 410	-3 092 281	-18 748 415
Depreciation of tangible fixed assets	-3 577	-3 577	-14 308
Other operating cost	-511 134	-149 633	-4 011 817
Operating loss	**-13 636 850**	**-4 470 697**	**-44 725 481**
Loss from financial items			
Interest income and similar income	1 980	735	1 840 942
Interest expenses and similar expenses	-1 598 415	-8	-5 297 093
Loss after financial items	**-15 233 285**	**-4 469 970**	**-48 181 632**
Loss before tax	**-15 233 285**	**-4 469 970**	**-48 181 632**
Loss for the period	**-15 233 285**	**-4 469 970**	**-48 181 632**

Parent company – Balance sheet

(SEK)	31 Mar 2024	31 Mar 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalised expenditures for development activities	204 095 702	150 960 551	182 483 295
Patents, trademarks, licenses and similar rights	13 780 255	11 452 967	13 780 255
	217 875 957	**162 413 517**	**196 263 550**
Tangible assets			
Fixtures, tools and installations	10 738	25 046	14 315
	10 738	**25 046**	**14 315**
Financial assets			
Shares in group company	941	941	941
	941	**941**	**941**
Total fixed assets	**217 887 636**	**162 439 505**	**196 278 806**
Current assets			
Current receivables			
Receivables from group companies	106 071	59 730	107 154
Other receivables	1 331 261	867 765	1 023 629
Prepaid expenses and accrued income	1 324 355	956 758	406 640
	2 761 687	**1 884 253**	**1 537 423**
Cash and bank balance	**49 110 483**	**41 281 024**	**87 102 526**
Total current assets	**51 872 170**	**43 165 277**	**88 639 949**
TOTAL ASSETS	**269 759 806**	**205 604 782**	**284 918 755**

Parent company – Balance sheet cont.

(SEK)	31 Mar 2024	31 Mar 2023	31 Dec 2023
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	23 377 523	13 751 484	23 377 523
Fund for development expenses	212 554 156	157 091 717	190 941 749
	235 931 680	**170 843 201**	**214 319 273**
Unrestricted equity			
Share premium reserve	51 688 498	55 565 517	51 688 498
Retained earnings	-71 313 630	-24 905 763	-1 519 591
Loss for the period	-15 233 285	-4 469 970	-48 181 632
	-34 858 418	**26 189 784**	**1 987 274**
Total equity	**201 073 262**	**197 032 985**	**216 306 547**
Long-term liabilities			
Other liabilities to credit institutions	400 000	400 000	400 000
Other long-term liabilities	45 000 000	-	45 000 000
	45 400 000	**400 000**	**45 400 000**
Current liabilities			
Accounts payable	18 561 391	3 884 491	6 930 366
Liabilities to group companies	-	261 989	-
Other liabilities	1 744 006	443 819	1 192 765
Accrued expenses and deferred income	2 981 148	3 581 498	15 089 077
	23 286 544	**8 171 797**	**23 212 208**
TOTAL EQUITY AND LIABILITIES	**269 759 806**	**205 604 782**	**284 918 755**

Parent company – Change in equity

01 January – 31 March 2024	Share capital	Fund for development expenses	Share premium reserve	Retained earnings	Net loss for the period
At start of period	23 377 523	190 941 749	51 688 498	-1 519 591	-48 181 632
Disposal according to AGM resolution	-	-	-	-48 181 632	48 181 632
Redistribution in equity	-	21 612 407	-	-21 612 407	-
Loss for the period	-	-	-	-	-15 233 285
At the end of the period	**23 377 523**	**212 554 156**	**51 688 498**	**-71 313 630**	**-15 233 285**

01 January – 31 March 2023	Share capital	Fund for development expenses	Share premium reserve	Retained earnings	Net loss for the period
At start of period	13 751 484	141 665 103	55 565 517	18 268 153	-27 747 301
Disposal according to AGM resolution	-	-	-	-27 747 301	27 747 301
Redistribution in equity	-	15 426 614	-	-15 426 614	-
Loss for the period	-	-	-	-	-15 233 285
At the end of the period	**13 751 484**	**157 091 717**	**55 565 517**	**-24 905 763**	**-15 233 285**

01 January – 31 December 2023	Share capital	Fund for development expenses	Share premium reserve	Retained earnings	Net loss for the period
At start of period	13 751 484	141 665 103	55 565 518	18 268 153	-27 747 301
Disposal according to AGM resolution	–	–	-55 565 518	27 818 216	27 747 301
Warrant issued				1 670 687	
New share issue	9 626 039	–	67 382 273	–	–
Issue expenses	–	–	-15 693 775	–	–
Redistribution in equity	–	49 276 646	–	-49 276 646	–
Loss for the period	–	–	–	–	-48 181 632
At the end of the period	**23 377 523**	**190 941 749**	**51 688 498**	**-1 519 591**	**-48 181 632**

Parent company – Cash flow statement

(SEK)	1 Jan 2024 31 Mar 2024 3 months	1 Jan 2023 31 Mar 2023 3 months	1 Jan 2023 31 Dec 2023 12 months
OPERATING ACTIVITIES			
Loss after financial items	-15 233 285	49 110 483	-48 181 632
Adjustments for items not included in the cash flow			
Depreciations	3 577	3 577	14 308
Accrued interest cost	-	-	777 040
Qualified stock warrants	-	-	1 670 687
	-15 229 708	**49 114 060**	**-45 719 597**
Cash flow from operating activities before changes in working capital	**-15 229 708**	**49 114 060**	**-45 719 597**
Cash flow from changes in working capital			
Increase (-)/Decrease (+) in operating receivables	-1 224 264	-306 317	40 152
Increase (+)/Decrease (-) in operating liabilities	74 336	-5 532 155	8 731 217
Cash flow from operating activities	**-16 379 636**	**43 275 588**	**-36 947 867**
Investing activities			
Acquisition of intangible assets	-21 612 407	-15 426 614	-49 276 646
Cash flow from investing activities	**-21 612 407**	**-15 426 614**	**-49 276 646**
Financing activities			
New share issue	-	-	77 008 311
Issue expenses	-	-	-15 693 775
Proceeds from borrowings	-	-	45 000 000
Cash flow from financing activities	**-**	**-**	**106 314 536**
Cash flow for the period	**-37 992 043**	**27 848 974**	**20 090 022**
Cash and cash equivalents at start of period	**87 102 526**	**67 012 503**	**67 012 503**
Cash and cash equivalents at end of period	**49 110 483**	**94 861 477**	**87 102 526**

The board and the managing director hereby certify that the interim report provides a fair overview of the parent company and the group's operations.

Gothenburg on 22 May 2024,

Joakim Söderström
Chair of the Board

Gunnar Olsson
Board member

Anders Svensson
Board member

Jeppe Øvlesen
Board member

Sten R. Sörensen
Chief Excutive Officer and Board member

Cereno Scientific

Cereno Scientific develops innovative treatments for common and rare cardiovascular disease. The lead drug candidate, CS1, is a HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Two initiatives performed during the ongoing Phase II study have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final study results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno also has two promising preclinical drug candidates in development through research collaborations with the University of Michigan. Investigational drug CS014 is a HDAC inhibitor in development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment potentially without the associated increased risk of bleeding in humans. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without increased risk of bleeding as documented in preclinical studies. In April 2024, Cereno submitted a Clinical Trial Application (CTA) for a Phase I First-in-Human-Study, expected to start during Q2 2024. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in several preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding, which also has been recognized in the medical community. CS585 was in-licensed from the University of Michigan in 2023. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.

Cereno Scientific AB
Org.nr. 556890–4071
Visiting and Postal address: BioVentureHub
Pepparedsleden 1, 431 83 Mölndal, Sweden
Tel: +46 768 66 77 87
www.cerenoscientific.com